GlassScriptPhysician profile
Sandra S Mccearley
NPI 1861590457
$9,520.78
in general payments reported to CMS, 2019-2025
30 companies · $534 in 2025
The $534 reported for 2025 was less than what a typical Clinical Cardiac Electrophysiology provider received nationally (typical 2025 total: $2,477).
See the full distribution for Clinical Cardiac Electrophysiology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $698 · 2020: $2,597 · 2021: $2,061 · 2022: $764 · 2023: $883 · 2024: $1,983 · 2025: $534.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,911 · Travel and Lodging: $1,489.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,911.32 |
| Travel and Lodging | $1,488.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,951.05 | 2021-2025 | Aveir, Jot Dx, Gallant |
| Boston Scientific Corporation | $2,319.73 | 2020-2025 | Patientcare Link, Cds - Mct/Cem Monitoring |
| Novartis Pharmaceuticals Corporation | $1,174.83 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $517.14 | 2019-2022 | |
| Medtronic, INC. | $467.83 | 2021-2024 | Linq II, Cobalt Dr Mri Surescan, Tyrx |
| Merck Sharp & Dohme LLC | $395.84 | 2021-2024 | Verquvo |
| Amgen INC. | $358.78 | 2019-2023 | Repatha |
| Janssen Pharmaceuticals, INC | $188.87 | 2019-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $165.87 | 2019-2022 | |
| Inspire Medical Systems, INC. | $149.54 | 2025 | Inspire |
| Pfizer INC. | $142.27 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $126.53 | 2019-2024 | Camzyos, Eliquis |
| Regeneron Healthcare Solutions, INC. | $88.70 | 2023-2025 | Evkeeza |
| Astrazeneca Pharmaceuticals LP | $64.30 | 2021-2023 | Farxiga |
| Daiichi Sankyo INC. | $57.83 | 2021-2024 | Injectafer |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Irhythm Technologies, INC. | $40.18 | 2019-2020 | |
| Kestra Medical Technology Services, INC. | $36.66 | 2025 | Assure Wcd |
| Alnylam Pharmaceuticals INC. | $36.43 | 2025 | Amvuttra |
| Esperion Therapeutics, INC. | $33.53 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $27.05 | 2025 | |
| Avinger INC. | $23.52 | 2021 | |
| Cardiva Medical, INC. | $21.81 | 2025 | Cardiva Vascade Mvp Vvcs 6-12f |
| Siemens Medical Solutions USA, INC. | $21.27 | 2025 | Artis Icono Biplane |
| Amarin Pharma, INC. | $19.96 | 2019 | |
| Terumo Medical Corporation | $19.71 | 2025 | Angio-Seal |
| Lexicon Pharmaceuticals, INC. | $18.09 | 2023 | Inpefa |
| Medtronic Vascular, INC. | $15.99 | 2019 | |
| Novo Nordisk INC | $13.96 | 2023 | Ozempic |
| Actelion Pharmaceuticals US, INC. | $12.09 | 2021 | |
| Sanofi-Aventis U.S. LLC | $11.42 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Mccearley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.